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Available online 9 January 2016Niemann–Pick C (NPC) disease is rare, neurodegenerative, lysosom-
al cholesterol storage disorder. Diagnosis of the disease is often delayed
due to disease heterogeneity, non-speciﬁc early visceral and neurologi-
cal symptoms, and lack of a rapid and reliable diagnostic assay. As a re-
sult, the disease progresses and opportunities to intervene tragically are
lost.
Until recently, the principal diagnostic test for NPC disease was
ﬁlipin staining of unesteriﬁed cholesterol in cultured ﬁbroblasts
obtained from a skin biopsy. While the ﬁlipin assay is sensitive for diag-
nosis of “classical” disease, it is unable to provide a ﬁrm diagnosis in
ﬁbroblasts with “variant” phenotypes that represent N1/3 of NPC cases
(Stampfer et al., 2013). Moreover, the test is invasive, performed only
at specialized centers, is costly (3000 USD), and generally entails ~3
month turnaround time, all of which are disincentives for broad clinical
deployment. Genetic analysis, involving sequencing of the NPC1 and
NPC2 genes, is an important diagnostic tool, though, due to cost consid-
erations, it is generally applied as a conﬁrmatory rather than screening
test. Furthermore, routine gene sequencing detects mutations on both
alleles in only 85% cases and is confounded by the highly polymorphic
nature of NPC1 (N400 known mutations), which makes interpretation
of new mutations challenging (Stampfer et al., 2013).
Over the past several years, biomarker discovery efforts have led to
identiﬁcation of several promising NPC disease biomarkers. One of
these markers, cholestane-3β,5α,6β-triol (“triol”), which is a cholester-
ol oxidation product, has emerged as a sensitive diagnostic for NPC
disease (Porter et al., 2010). The application of this biomarker to rapid
diagnosis of NPC has been demonstrated at multiple centers and on
diverse platforms (Boenzi et al., 2014; Klinke et al., 2015; Pajares et al.,
2015; Polo et al., 2015; Jiang et al., 2011). In this issue of EBioMedicine,DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.12.018.
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agnostics for NPC disease using the triol assay (Reunert et al., 2016).
From 1902 suspectedNPC patients, 69 NPC1, 2 NPC2, and 12 NP-A/B pa-
tients were identiﬁed. Identiﬁcation of 71 new NPC patients over a
three-year period by a single clinical laboratory is unprecedented, dem-
onstrating the utility of the triol assay as a rapid and reliable means to
screen patients suspected of NPC. It is noteworthy that 40% of the diag-
noseswere among patients N20 years of age, conﬁrming suspicions that
the disorder is underdiagnosed in the adult population, and hinting that
the incidence of NPCmay be higher than previously reported. Bolstered
by experience from more than two dozen laboratories worldwide, the
report from Reunert et al. strongly support the authors' recommenda-
tion that the triol assay become the diagnostic standard for NPC screen-
ing, replacing the less sensitive, qualitative, and time-consuming ﬁlipin
staining test as the ﬁrst-line NPC diagnostic assay.
The growing experiencewith the triol biomarker in clinical laborato-
ries also provides important insight into the limitations of the assay. Al-
though triol is a highly sensitive marker for detection of NPC, it has
broader speciﬁcity than originally reported, extending beyond NPC to
related disorders of sterol metabolism. Plasma triol, which is generated
by non-enzymatic oxidation of cholesterol, is similarly elevated in the
setting of NP-A/B (ASMD, acid sphingomyelinase deﬁciency), cerebro-
tendinous xanthomatosis (CTX), and lysosomal acid lipase deﬁciency
(LALD) (Klinke et al., 2015; Pajares et al., 2015; Reunert et al., 2016).
In addition, the plasma triol assay may be falsely elevated in neonates
with non-NPC cholestasis (Polo et al., 2015). Whether the elevated
triol in these conditions is due to increased formation in vivo, endoge-
nous interference, or artifact generated by sample handling or to gener-
ation of the labile 5,6-epoxycholesterol intermediate, which can be
converted into non-endogenous triol during the storage and sample
preparation (e.g., by chemical derivatization), remains to be deter-
mined. Finally, approximately 25% of NPC carriers have plasma triol
levels that overlap with NPC patients, confounding interpretation of
test results (Jiang et al., 2011; Reunert et al., 2016).
What might we look for in an ideal NPC diagnostic test? Such a test
would be based on an analyte that can be detected bymass spectrome-
trywithout need for derivatization,which can introduce artifact into the
assay. The test would display exceptional sensitivity and speciﬁcity for
NPC, and further permit unambiguous discrimination betweenNPC car-
riers and patients, and could be used for screening neonates with chole-
stasis, a population known to be enriched for NPC. Ideally, the analyte
would be stable at room temperature and during long-term storage,
which would simplify NPC diagnostics, allowing clinicians from any-
where in the world to send samples to clinical labs without need forthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
19X. Jiang, D.S. Ory / EBioMedicine 4 (2016) 18–19dry ice or overnight shipments. A dried blood spot-based assay would
also have the advantage of potential integration into existing newborn
screening platforms.
In addition to triol, several other NPC diseasemarkers have been de-
scribed and explored as NPC diagnostics (Giese et al., 2015; Welford
et al., 2014). Understanding of the relativemerits of eachmarker awaits
rigorous benchmarking in the clinical laboratory setting. Broad dissem-
ination of assays based on this new generation of biochemical markers
would be expected to eliminate the diagnostic delay that at present
exceeds ﬁve years. Furthermore, newborn screens based on these bio-
markers would provide more accurate assessment of the true disease
incidence and facilitate therapeutic intervention in pre-symptomatic
patients. Ultimately, advancement in diagnostics will enable initiation
of therapy in neonates and change the natural history of the disease,
prolonging the asymptomatic phase before onset of neurological symp-
toms, increasing lifespan, and improving quality of life.
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